arginine and serine rich coiled-coil 2Genealiases: []
Q-omics provides the consensus-scored RSRC2 profile across patient tissues and cancer cell-line models. RSRC2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, RSRC2 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, RSRC2 protein abundance shows 26,836 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, HNSC, and LSCC as cancer lineages where RSRC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RSRC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RSRC2 survival associations across molecular data types. RSRC2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RSRC2 RNA expression–survival associations across cancer types. High RSRC2 expression shows unfavorable associations in LIHC, ACC, UVM and COAD, but favorable associations in UCS and BRCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for RSRC2 RNA expression.
This table summarizes RSRC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RSRC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RSRC2 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, STAD and BLCA. The HNSC box plot shows higher RSRC2 RNA expression in tumor versus normal tissue (log2 FC = +0.650, t-test p < 0.001).
This table shows molecular features associated with RSRC2 in patient tissues and cancer cell lines. In patient samples, RSRC2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RSRC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
